Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-07-10
2007-07-10
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100
Reexamination Certificate
active
10506225
ABSTRACT:
Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1–3 and kringles 1–4.
REFERENCES:
patent: 6235713 (2001-05-01), Achen et al.
Mullingan-Kehoe et al, J Biol Chem 276(11): 8588-8596, Mar. 2001.
Mason et al, Molecular Endocrinology 8(3): 325-332, 1994.
Gura et al, Science 278: 1041-1042, Nov. 1997.
Dermer, Bio/Technology 12: 320, 1994.
Kang et al., “Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH”, Gene 2001 267:233-242.
Kitareewan et al., “UBE1L is a retinoid target that triggers PML/RARα degradation and apoptosis in acute promyelocytic leukemia”, Proc. Natl. Acad. Sci. USA 2002 99: (6) :3806-3811.
Mulligan-Kehoe et al., “A Truncated Plasminogen Activator Inhibitor-1 Protein Blocks the Availability of Heparin-binding Vascular Endothelial Growth Factor A Isoforms”, J Biol Chem 2002 277 (50) :49077-49089.
Mulligan-Kehoe Mary Jo
Powell Richard J.
Chan Christina
Huynh Phuong
Licata & Tyrrell P.C.
Trustees of Dartmouth College
LandOfFree
Methods for modulating angiogenesis via VEGF does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating angiogenesis via VEGF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating angiogenesis via VEGF will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3778668